Allergan wins US patent protection for Combigan until 2022
This article was originally published in Scrip
Executive Summary
A Texas federal judge ruled in favour of Allergan on 22 August in consolidated patent suits which accused generics makers of infringing four US patents covering the combination eyedrop product Combigan (brimonidine tartrate 0.2% plus timolol maleate ophthalmic solution 0.5%).